Vertex Pharmaceuticals Incorporated engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide. Its products include telaprevir, a Phase IIb clinical trial product for the treatment of hepatitis C virus infection; VX-702, a Phase II clinical trial product for rheumatoid arthritis and other inflammatory diseases; VX-770, a Phase I clinical trial product for cystic fibrosis; and VX-883, a preclinical stage product for bacterial infection. The company also offers Lexiva/Telzir for the treatment of HIV infection and AIDS under the collaboration with GlaxoSmithKline, as well as develops MK-0457 and MK-6592, which are in...